Halina Offner
Corporate Officer/Principal en Artielle ImmunoTherapeutics, Inc. .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Gilbert N. Miller | M | - |
Artielle ImmunoTherapeutics, Inc.
Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | 23 años |
Peter C. M. McWilliams | M | - |
Artielle ImmunoTherapeutics, Inc.
Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | - |
Arthur A. Vandenbark | M | - |
Artielle ImmunoTherapeutics, Inc.
Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | 20 años |
Peter O. Kohler | M | 85 |
Oregon Health & Science University
| 36 años |
Brock Metcalf | M | - |
Artielle ImmunoTherapeutics, Inc.
Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | - |
Brian Druker | M | 68 |
Oregon Health & Science University
| 31 años |
Rick L. Bentzinger | M | - |
Oregon Health & Science University
| 19 años |
Vincent Price | M | 60 |
Oregon Health & Science University
| - |
Jessica Castle | M | - |
Oregon Health & Science University
| - |
Derick Vivier | M | - |
Oregon Health & Science University
| - |
Daisy Alva | F | - |
Oregon Health & Science University
| - |
Erik Brodt | M | - |
Oregon Health & Science University
| - |
Kristen Beiers-Jones | F | - |
Oregon Health & Science University
| - |
Michael C. Heinrich | M | - |
Oregon Health & Science University
| - |
Rose McPharlin | F | - |
Oregon Health & Science University
| - |
Stefanie Petrie | F | - |
Oregon Health & Science University
| - |
Dennis Koop | M | - |
Oregon Health & Science University
| - |
Aaron Nilsen | M | - |
Oregon Health & Science University
| - |
Lev Fedorov | M | - |
Oregon Health & Science University
| - |
Kellie Guentert | F | - |
Oregon Health & Science University
| - |
Cary O. Harding | M | - |
Oregon Health & Science University
| 25 años |
Misha Pavel | M | - |
Oregon Health & Science University
| - |
Tomasz Beer | M | - |
Oregon Health & Science University
| - |
Matthew C. Riddle | M | - |
Oregon Health & Science University
| - |
David E. Battaglia | M | - |
Oregon Health & Science University
| - |
Holly Jimison | M | - |
Oregon Health & Science University
| - |
Nancy Press | M | - |
Oregon Health & Science University
| - |
Yong Hong Yan | M | 57 |
Oregon Health & Science University
| - |
Shahab Fatheazam | M | 72 |
Artielle ImmunoTherapeutics, Inc.
Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | 20 años |
Christopher Dubay | M | - |
Oregon Health & Science University
| - |
Erwin Schwarz | M | - |
Oregon Health & Science University
| 25 años |
William Thoma | M | - |
Oregon Health & Science University
| - |
Mary H. Oldshue | F | 72 |
Oregon Health & Science University
| - |
Michael McLean | M | - |
Oregon Health & Science University
| - |
Rocky Dixon | M | - |
Oregon Health & Science University
| - |
Henry Hollis Hewitt | M | 82 |
Oregon Health & Science University
| - |
Chad Waite | M | 69 |
Oregon Health & Science University
| - |
Scott Hansen | M | - |
Oregon Health & Science University
| - |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Adolph J. Ferro | M | - |
Artielle ImmunoTherapeutics, Inc.
Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | - |
Gregory G. Burrows | M | - |
Artielle ImmunoTherapeutics, Inc.
Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | - |
Andrew S. Goldstein | M | - |
Artielle ImmunoTherapeutics, Inc.
Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | 5 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 41 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Halina Offner
- Red Personal